Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD14 Protein, Fc tag,100µg  

Recombinant human CD14 Protein, Fc tag,100µg

Recombinant Human CD14 Protein (Thr20-Cys352), produced in human 293 cells (HEK293), Fc tag

Synonym
Recombinant Human Protein, CD14, CD-14

More details

CD4-H5252-100

Availability: within 7 days

312,00 €

Background
Cluster of differentiation 14 (CD14), is a cell surface glycoprotein, and is a is a component of the innate immune system. CD14 is a myelomonocytic differentiation antigen preferentially expressed on monocytes, macrophages, and activated granulocytes. CD14 exists in two forms. Either it is anchored into the membrane by a glycosylphosphatidylinositol tail (mCD14) or it appears in a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).[1] CD14 acts as a co-receptor (along with the Toll-like receptor TLR 4 and MD-2) for the detection of bacterial lipopolysaccharide (LPS).[2-3] CD14 can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). CD14 has been proposed to be involved in various biological processes, including transportation of other lipids, cell-cell interaction during different immune responses, as well as recognition of apoptotic cells. Although LPS is considered its main ligand, CD14 also recognizes other pathogen-associated molecular patterns. CD14+ cells are monocytes that can differentiate into a host of different cells. CD14 has been shown to interact with Lipopolysaccharide-binding protein.[4- 5] 

Source
Human CD14, Fc Tag (CD4-H5252) is expressed from human 293 cells (HEK293). It contains AA Thr 20 - Cys 352 (Accession # P08571-1).
Predicted N-terminus: Thr 20

Molecular Characterization
rhCD14-Fc, contains eleven leucine-rich repeats regions and five glycosylation sites in CD14 protein sequence, and fused with Fc fragment of human IgG1 at the C-terminus and has a calculated MW of 62.4 kDa expressed. The predicted N-terminus is Thr20. Due to different glycosylation, DTT-reduced protein migrates as 75-85 kDa polypeptide.

Endotoxin
Less than 1.0 EU per μg of the rhCD14-Fc by the LAL method.

Purity
>97% as determined by SDS-PAGE.

Formulation
Supplied as a 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0 and delivered as liquid formulation or lyophilized powder. Normally mannitol or trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A

References

(1)Kirkland TN, Viriyakosol S, et al., 1998, Prog. Clin. Biol. Res. 397: 79–87.
(2)Kitchens RL., 2000, Chem. Immunol.. Chemical Immunology and Allergy 74: 61–82.
(3)Tapping RI, Tobias PS., 2000, Chem. Immunol.. Chemical Immunology and Allergy 74: 108–21.
(4)Thomas, Celestine J., et al., 2002, FEBS Lett. (Netherlands) 531 (2): 184–8.
(5)Yu B, Wright S D., 1995, J. Inflamm. (UNITED STATES) 45 (2): 115–25.